Navigation Links
NovoCure Ltd. announces closing of financing round
Date:9/28/2009

ntly completed enrollment of a 236-patient, multi-center, randomized Pivotal clinical trial studying the safety and efficacy of the Novo-TTF device treating patients with recurrent GBM compared to standard-of-care chemotherapy. The results of this trial will be presented to the Food and Drug Administration (FDA) as part of a PMA application planned for early next year.

A new, multi-center, Pivotal clinical trial to study the efficacy of the novel Novo-TTF device in combination with standard-of-care chemotherapy (temozolomide) compared to standard-of-care chemotherapy alone in patients with newly-diagnosed GBM is now open in the United States, Europe and Israel. Data from a Pilot study of Novo-TTF in combination with chemotherapy in patients with newly diagnosed GBM suggest that the device may significantly improve upon the standard-of-care when used in combination with chemotherapy. As published in BMC Medical Physics in January of this year, patients treated with TTFields in a Pilot clinical trial for newly diagnosed GBM showed a median time to disease progression of 155 weeks compared to approximately 31weeks for concurrent control patients receiving standard-of-care chemotherapy alone. With 80% still living at the time of publication, the TTF treated patients had not yet reached the median overall survival at 39 months, compared to historical published median overall survival of 14.6 months for newly diagnosed GBM patients receiving standard-of-care chemotherapy alone. The ability to add the Novo-TTF to standard-of-care chemotherapy with minimal additional toxicity makes the treatment particularly attractive. Details about the newly diagnosed GBM trial including trial locations can be found on the NovoCure website (www.novocuretrial.com).


'/>"/>

Contact: Jennifer Paganelli Schwartz
jennifer.schwartz@edelman.com
212-642-7774
Edelman Public Relations
Source:Eurekalert

Page: 1 2

Related medicine news :

1. NovoCure presents results from breast cancer pilot study
2. RCRC Independent Review Board Announces DHHS Research Oversight
3. change:healthcare Announces Twitter Application that brings Healthcare Information and Costs to Consumers' Fingertips
4. QRxPharma Announces Strategic Alliance with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets
5. I-Therapeutix, Inc. Announces Company Name Change
6. President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors
8. US Farms, Inc. Announces Broker Network Agreement With Sunshine Specialties for Aloe365 Products
9. ReBuilder Medical Technologies, Inc. Announces Medicare Billing Ability for its ReBuilder Product
10. Cardiogenesis Announces Successful Symposium at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting
11. Strategic Information Group Announces QAD Enterprise Validation Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
(Date:3/28/2015)... 28, 2015 Purity Products®, a ... announces the release of their revolutionary new weight ... two randomized, double-blind, placebo-controlled clinical studies to be ... hip size. MuffinStop™ is a combination of two ... mangostana, fused together to create one of the ...
(Date:3/27/2015)... 27, 2015 Wellness for Cancer–the first ... criteria for the spa and wellness industry–has certified Hands ... have experienced or are living with cancer. Hands ... 365® Network, will be identified with a special Wellness ... provider of safe, therapeutic services for cancer patients. , ...
(Date:3/27/2015)... First Choice Emergency Room opened ... is located 12665 W Lake Houston Pkwy, Houston, Texas and ... I look forward to delivering the highest quality emergency medical ... Director of First Choice Emergency Room Summerwood. , ... donation to Summer Creek High School at First Choice Emergency ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 On ... EcoLuxe Lounge in the Stardust Penthouse on the ... Durkin, Los Angeles’ leading sustainable product TV and ... this unforgettable day-long event, which featured some of ... ecologically sound products and services. , “We were ...
Breaking Medicine News(10 mins):Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2
... not all , WEDNESDAY, Oct. 17 (HealthDay News) -- There,s ... , That,s the conclusion of Israeli researchers who reviewed three ... to sham insoles or no treatment for back pain prevention. ... 256 people that focused on the use of insoles for ...
... SuperGen Inc.,(Nasdaq: SUPG ), a pharmaceutical ... of therapies for solid tumors and,hematological malignancies, today ... presentations at the AACR-NCI-EORTC International,Conference from Oct. 22-26 ... The poster presentations will focus on data concerning ...
... is Now Supported to Help Advance Research-, ... within the biomedical market for its innovative genomic ... Release 1.3,of SLIM Search. The SLIM Search genomic ... biomedical research and development.,Version 1.3 includes the following ...
... 17 /Xinhua-PRNewswire/ -- Mindray Medical,International Limited (NYSE: MR ... in China, today announced that it will report,its third ... on,November 1, 2007. Mindray,s management will hold an earnings ... Eastern Time (8:00 AM on November,2, 2007 Beijing/Hong Kong ...
... completing its review of safety,and efficacy data currently ... recommended that the pivotal Phase 3 clinical,trial FAME(TM) ... the current protocol, without change. The trial is ... of diabetic macular edema (DME). FAME is ...
... Oct. 17 Mirixa Corporation, a leading,developer ... facilitate,pharmacist-based patient care services, today announced the ... customized for each,participating pharmacy. RxFYI is free ... patient loyalty and generate revenue. "Patients ...
Cached Medicine News:Health News:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference 2Health News:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference 3Health News:Release 1.3 of SLIM Search Now Available 2Health News:Mindray to Report Third Quarter 2007 Financial Results on November 1, 2007 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 3Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 4Health News:Mirixa Debuts RxFYI - a Free Pharmacy-Published Health eNewsletter Building Patient Loyalty and Generating Revenue 2
(Date:3/27/2015)... YORK , March 27, 2015  Delcath ... pharmaceutical and medical device company focused on oncology ... and metastatic liver cancers, announces the reporting of ... Company,s Melphalan Hydrochloride for Injection with the Delcath ... a poster presentation at the Society of Surgical ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... with a focus on Omega-3 therapies for cardiovascular disease ... it issued 763,752 common shares of the Corporation (the ... for the period of December 5 th , 2014 ... Convertible Notes that is due on or before April ...
(Date:3/26/2015)... Cardiologists at Beaumont Hospital, Royal ... implant of a device recently approved by the Food ... The Watchman Left Atrial Appendage Closure implant is an ... reduce the risk of stroke. Atrial fibrillation ... than 5 million Americans. Twenty percent of all strokes ...
Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
... BRISBANE, Calif., Sept. 13 InterMune, Inc. (Nasdaq: ... related to the company,s development program for pirfenidone and ... Annual Congress of the European Respiratory Society (ERS), to ... Dan Welch, Chairman, Chief Executive Officer and President of ...
... Sept. 13 /PRNewswire-Asia-FirstCall/ -- ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
Cached Medicine Technology:InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 2InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 3InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 4InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 5Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 2Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 3Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 4Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 5Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 6Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 7
A stable revision design with extensive sizes...
Severe revision options for the knee and hip...
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Medicine Products: